Summary
Four subjects received 5 mg14C-glipizide orally, 3 subjects 1 mg intravenously and 2 subjects 5 mg14C-glibenclamide orally. Plasma levels of radioactivity, and urinary and faecal excretion were measured. For both drugs the disappearance of radioactivity from plasma followed complex kinetics and the apparent half-lives increased steadily with time. The two sulfonylureas were extensively metabolized and were excreted in the urine as hydroxylated or conjugated metabolites. The effects of both drugs on blood glucose and immunoreactive insulin were comparable. The findings are compared with other published results.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Schmidt, H.A.E., Petrides, P.: Glukose- und HB-419-Konzentration im Blut sowie HB 419-Ausscheidung im Urin nach einmaliger oraler Applikation von HB 419 -14C. Arzneimittel-Forsch.19 1422 - 1428 (1969)
Rupp, W., Christ, O., Heptner, W.: Resorption, Ausscheidung und Metabolismus nach intra-venöser und oraler Gabe von HB 419 -14C an Menschen. Arzneimittel-Forsch.19 1428–1434 (1969)
Anderson, J., Stephenson, R.J., Tomlinson, R.W.S., Weinberg, A.L.: Studies with14C-labelled glibenclamide. Postgrad. med. J.46 (Dec. Suppl.), 42–45 (1970)
Rupp, W., Christ, O., Fülberth, W.: Unter-suchungen zur Bioavailability von Glibenclamid. Arzneimittel-Forsch.22 471–473 (1972)
Fucella, L.M., Tamassia, V., Valzelli, G.: Metabolism and kinetics of the hypoglycemic agent glipizide. Comparison with glibenclamide. J. clin. Pharmacol.13 68–75 (1973)
Ambrogi, V., Artini, D., Fucella, L.M., Goldaniga, G., Orsini, G., Ronchi, R., Tamassia, V., Valzelli, G., Angelucci, R.: Farmacocinetica e metabolismo in animali da esperimento e nell'uomo della N-{4-[β-(5-metilpirazina-2-carbossiamido)-etil]-benzensolfonil}-N'-cicloesil-urea (K 4024) Boll. chim. farm.3 251–264 (1972)
Taylor, J.A.: K 4024 (Glydiazinamide). I. Pharmacokinetic studies in man. Pfizer Inc. Groton, Conneticut, Internal communication
Schmidt, H.A.E., Schoog, M., Schweer, K.H., Winkler, E.: Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered C14-glipizide, a new antidiabetic. Diabetologia9 (Suppl.) 320–330 (1973)
Balant, L., Zahnd, G., Gorgia, A., Schwarz, R., Fabre, J.: Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia9 (Suppl.) 331–338 (1973)
Zender, R.: Une micromethode automatique pour l'analyse quantitative des aldohexoses dans les liquides biologiques par l'o-toluidine. Clin. chim. Acta8 351–358 (1963)
Hales, C.N., Randle, P.Y.: Immunoassay of insulin with insulin-antibody precipitate. Biochem. J.88 137–146 (1963)
Dost, F.H.: Grundlagen der Pharmakokinetik. Stuttgart: Georg Thieme Verlag 1968
Heptner, W., Kellner, H.N., Christ, O., Weihrauch, D.: Metabolismus von HB 419 im Tier. Arzneimittel-Forsch.19 1400–1404 (1969)
Dettli, L.: Dosierungstheorie für die repetierte Applikation reversibel wirkender Pharmaka bei Eliminationsinsuffizienz. In: Pharmacological and clinical significance of pharmacokinetics, pp. 31–41, Stuttgart: F.K. Schattauer Verlag 1970
Garrett, E.R.: The clinical significance of pharmacokinetics. In: Pharmacological and clinical significance of pharmacokinetics, pp. 5–21. Stuttgart: F.K. Schattauer Verlag 1970
Doluisio, J.T., Dittert, L.W.: Influence of repetitive dosing of tetracyclines on biological half-life in serum. Clin. Pharmacol. Ther.10 690–701 (1969)
Fabre, J., Kunz, J.P., Virieuy, C., Laurencet, J.L., Pitton J.S.: Le comportement de la doxycycline chez l'homme. Chemotherapy13 (Suppl.) 23–40 (1968)
Gibaldi, M.: Pharmacokinetic aspects of drug metabolism. Ann. N.Y. Acad. Sci.179 19–31 (1971)
Schmidt, F.H., Hrstka, V.E.: Radio-immunoassay of glibenclamide: minimum effective dose levels and pharmacodynamics. XIIeCongrès International de Thérapeutique, Genève 1973
Fabre, J., Balant, L., Zahnd, G.: Pharmacocinétique des nouvelles sulfonylurées dans les conditions normales et pathologiques. XIIeCongrès International de Thérapeutique, Genève 1973
Schulz, E., Koch, K., Schmidt, F.H.: Ursachen der Potenzierung der hypoglykämischen Wirkung von Sulfonylharnstoff-Derivaten durch Medikamente. II. Pharmakokinetik und Metabolismus von Glibenclamid (HB 419) in Gegenwart von Phenylbutazon. Europ. J. clin. Pharmacol.4 32–37 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Balant, L., Fabre, J. & Zahnd, G.R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 8, 63–69 (1975). https://doi.org/10.1007/BF00616416
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00616416